TY - JOUR
T1 - Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer
AU - Casanova-Salas, Irene
AU - Athie, Alejandro
AU - Boutros, Paul C.
AU - Del Re, Marzia
AU - Miyamoto, David T.
AU - Pienta, Kenneth J.
AU - Posadas, Edwin M.
AU - Sowalsky, Adam G.
AU - Stenzl, Arnulf
AU - Wyatt, Alexander W.
AU - Mateo, Joaquin
N1 - Funding Information:
Funding/Support and role of the sponsor: Irene Casanova-Salas was supported by a PERIS fellowship from the Departament de Salut Generalitat de Catalunya ( SLT008/18/00185 ), and by a fellowship from “la Caixa” Foundation ( ID 100010434 ) and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement number 847648 . The fellowship code is LCF/BQ/PI20/11760033. This work was supported in part by the Intramural Research Program of the National Cancer Institute, NIH ; by the NIH/NCI under award number P30CA016042 ; and through an operating grant from the Early Detection Research Network ( 1U01CA214194-01 ) to Paul C. Boutros. The authors affiliated to VHIO (Irene Casanova-Salas, Alejandro Athie, and Joaquin Mateo) acknowledge funding from the Cellex Foundation , and “la Caixa” Foundation (LCF/PR17/51120011)), AECC (Spanish Association Against Cancer) Scientific Foundation , and Fundacion FERO . Joaquin Mateo acknowledges support from the Instituto de Salud Carlos III (grant PI18/01384 ) and Prostate Cancer Foundation Young Investigator program .
Funding Information:
Funding/Support and role of the sponsor: Irene Casanova-Salas was supported by a PERIS fellowship from the Departament de Salut Generalitat de Catalunya (SLT008/18/00185), and by a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement number 847648. The fellowship code is LCF/BQ/PI20/11760033. This work was supported in part by the Intramural Research Program of the National Cancer Institute, NIH; by the NIH/NCI under award number P30CA016042; and through an operating grant from the Early Detection Research Network (1U01CA214194-01) to Paul C. Boutros. The authors affiliated to VHIO (Irene Casanova-Salas, Alejandro Athie, and Joaquin Mateo) acknowledge funding from the Cellex Foundation, and “la Caixa” Foundation (LCF/PR17/51120011)), AECC (Spanish Association Against Cancer) Scientific Foundation, and Fundacion FERO. Joaquin Mateo acknowledges support from the Instituto de Salud Carlos III (grant PI18/01384) and Prostate Cancer Foundation Young Investigator program.
Funding Information:
Financial disclosures: Joaquin Mateo certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: P.C. Boutros is a member of the Scientific Advisory Boards of BioSymetrics Inc. and Intersect Diagnostics Inc. M. Del Re is a consultant for Ipsen, Janssen, Sanofi-Aventis, and Novartis. K.J. Pienta is a consultant for Cue Biopharma, Inc.; is a founder of Keystone Biopharma, Inc.; and receives research support from Progenics, Inc. J. Mateo has served on scientific advisory boards from Amgen, AstraZeneca, Clovis Oncology, Janssen, Merck/MSD, and Roche; has participated in speaker bureaus from AstraZeneca, Pfizer, Janssen, Sanofi, and Astellas Pharma; and has received research funding from AstraZeneca and Pfizer Oncology through grants to the institution. The remaining authors have nothing to disclose.
Publisher Copyright:
© 2021 The Authors
PY - 2021/6
Y1 - 2021/6
N2 - Context: Genomic stratification can impact prostate cancer (PC) care through diagnostic, prognostic, and predictive biomarkers that aid in clinical decision-making. The temporal and spatial genomic heterogeneity of PC together with the challenges of acquiring metastatic tissue biopsies hinder implementation of tissue-based molecular profiling in routine clinical practice. Blood-based liquid biopsies are an attractive, minimally invasive alternative. Objective: To review the clinical value of blood-based liquid biopsy assays in PC and identify potential applications to accelerate the development of precision medicine. Evidence acquisition: A systematic review of PubMed/MEDLINE was performed to identify relevant literature on blood-based circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs) in PC. Evidence synthesis: Liquid biopsy has emerged as a practical tool to profile tumor dynamics over time, elucidating features that evolve (genome, epigenome, transcriptome, and proteome) with tumor progression. Liquid biopsy tests encompass analysis of DNA, RNA, and proteins that can be detected in CTCs, ctDNA, or EVs. Blood-based liquid biopsies have demonstrated promise in the context of localized tumors (diagnostic signatures, risk stratification, and disease monitoring) and advanced disease (response/resistance biomarkers and prognostic markers). Conclusions: Liquid biopsies have value as a source of prognostic, predictive, and response biomarkers in PC. Most clinical applications have been developed in the advanced metastatic setting, where CTC and ctDNA yields are significantly higher. However, standardization of assays and analytical/clinical validation is necessary prior to clinical implementation. Patient summary: Traces of tumors can be isolated from blood samples from patients with prostate cancer either as whole cells or as DNA fragments. These traces provide information on tumor features. These minimally invasive tests can guide diagnosis and treatment selection.
AB - Context: Genomic stratification can impact prostate cancer (PC) care through diagnostic, prognostic, and predictive biomarkers that aid in clinical decision-making. The temporal and spatial genomic heterogeneity of PC together with the challenges of acquiring metastatic tissue biopsies hinder implementation of tissue-based molecular profiling in routine clinical practice. Blood-based liquid biopsies are an attractive, minimally invasive alternative. Objective: To review the clinical value of blood-based liquid biopsy assays in PC and identify potential applications to accelerate the development of precision medicine. Evidence acquisition: A systematic review of PubMed/MEDLINE was performed to identify relevant literature on blood-based circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs) in PC. Evidence synthesis: Liquid biopsy has emerged as a practical tool to profile tumor dynamics over time, elucidating features that evolve (genome, epigenome, transcriptome, and proteome) with tumor progression. Liquid biopsy tests encompass analysis of DNA, RNA, and proteins that can be detected in CTCs, ctDNA, or EVs. Blood-based liquid biopsies have demonstrated promise in the context of localized tumors (diagnostic signatures, risk stratification, and disease monitoring) and advanced disease (response/resistance biomarkers and prognostic markers). Conclusions: Liquid biopsies have value as a source of prognostic, predictive, and response biomarkers in PC. Most clinical applications have been developed in the advanced metastatic setting, where CTC and ctDNA yields are significantly higher. However, standardization of assays and analytical/clinical validation is necessary prior to clinical implementation. Patient summary: Traces of tumors can be isolated from blood samples from patients with prostate cancer either as whole cells or as DNA fragments. These traces provide information on tumor features. These minimally invasive tests can guide diagnosis and treatment selection.
KW - Circulating tumor DNA
KW - Circulating tumor cell
KW - Extracellular vesicles
KW - Genomics
KW - Liquid biopsy
KW - Precision medicine
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85099146563&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099146563&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2020.12.037
DO - 10.1016/j.eururo.2020.12.037
M3 - Review article
C2 - 33422353
AN - SCOPUS:85099146563
VL - 79
SP - 762
EP - 771
JO - European Urology
JF - European Urology
SN - 0302-2838
IS - 6
ER -